<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834678</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-08164</org_study_id>
    <secondary_id>NCI-2011-03164</secondary_id>
    <nct_id>NCT00834678</nct_id>
  </id_info>
  <brief_title>Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer</brief_title>
  <official_title>Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Comprehensive Cancer Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.
      Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
      growth and by blocking blood flow to the tumor. Giving bendamustine together with erlotinib
      may kill more tumor cells.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of giving
      bendamustine together with erlotinib in treating patients with stage IIIB, stage IIIC, or
      stage IV breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the phase II dose and assess the toxicity of bendamustine hydrochloride and
           erlotinib hydrochloride in patients with triple-receptor (estrogen receptor,
           progesterone receptor, and HER-2)-negative, stage IIIB, IIIC, or IV breast cancer.
           (Phase I)

        -  To determine the efficacy of this regimen in these patients. (Phase II)

      Secondary (Correlative)

        -  To assess the correlation between tumor EGFR expression and EGFR gene amplification and
           treatment efficacy and toxicity.

        -  To assess for differences in treatment efficacy between basal-like and non-basal-like
           cancers.

        -  To assess for differences in treatment efficacy between tumors with and without
           expression of DNA damage-response (DDR) checkpoint proteins.

        -  To assess for differences in the activation state of DDR checkpoint proteins based on
           breast cancer subtype.

      OUTLINE: This is a multicenter, phase I dose-escalation study followed by a phase II study.

      Patients receive bendamustine hydrochloride IV over 30 minutes on days 1-2 and oral erlotinib
      hydrochloride once daily on days 5-21. Treatment repeats every 28 days for at least 6 courses
      in the absence of disease progression or unacceptable toxicity.

      Patients with no evidence of disease progression may continue with daily single-agent oral
      erlotinib hydrochloride on days 1-28. Treatment continues every 28 days in the absence of
      disease progression or unacceptable toxicity.

      Breast cancer tissue blocks from prior procedures are obtained for correlative studies. After
      a tissue microarray (TMA) and a TMA map are prepared, TMA slides are used for hematoxylin and
      eosin (H&amp;E) staining, FISH, and IHC.

      After completion of study treatment, patients are followed every 3 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2009</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated Dose of Bendamustine Hydrochloride (Phase I)</measure>
    <time_frame>Up to two years</time_frame>
    <description>28 day cycle included intravenous bendamustine on days 1 and 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum-tolerated Dose of Erlotinib Hydrochloride (Phase I)</measure>
    <time_frame>Up to two years</time_frame>
    <description>28 day cycle included intravenous erlotinib on days 15-21.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting Toxicity (Phase I)</measure>
    <time_frame>Up to two years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival at 6 Months and 12 Months (Phase II)</measure>
    <time_frame>Up to two years</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to two years</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>Up to two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>Up to two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>from time of study enrollment until death, for up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of EGFR Expression or Amplification, Basal-like Tumors, and DNA Damage-repair Checkpoint Activation With ORR, CBR, DR, and OS</measure>
    <time_frame>up to two years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Bendamustine and Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 - 21 of each 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bendamustine</intervention_name>
    <description>100 or 120 mg/m2 IV on days 1 and 2</description>
    <arm_group_label>Bendamustine and Erlotinib</arm_group_label>
    <other_name>Ribomustin</other_name>
    <other_name>Treanda</other_name>
    <other_name>SDX- 105</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>100 or 150 mg po on days 5 - 21 of each 28 day cycle</description>
    <arm_group_label>Bendamustine and Erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance erlotinib</intervention_name>
    <description>150 mg po daily (days 1 - 28 of 28 day cycle)</description>
    <arm_group_label>Bendamustine and Erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed breast cancer meeting 1 of the following criteria:

               -  Unresectable stage IIIB or IIIC disease

               -  Stage IV disease

          -  Must be negative for all of the following:

               -  Estrogen receptor (&lt; 10%)

               -  Progesterone receptor (&lt;10%)

               -  HER-2 (negative FISH, IHC 0 - 1+, or IHC +2 with negative FISH)

          -  Measurable or evaluable disease

          -  No symptomatic or progressive CNS (central nervous system) metastases

               -  Previously treated CNS metastases allowed provided all of the following criteria
                  are met:

                    -  At least 8 weeks since prior radiation to brain or CNS metastases

                    -  No concurrent steroids

                    -  No leptomeningeal disease

        PATIENT CHARACTERISTICS:

          -  Menopausal status not specified

          -  ECOG (Eastern Cooperative Oncology Group) performance status 0-2

          -  Life expectancy â‰¥ 6 months

          -  WBC &gt; 1,500/mmÂ³

          -  Platelet count &gt; 100,000/mmÂ³

          -  Creatinine clearance &gt; 40 mL/min

          -  Normal electrolytes (i.e., Na, K, and Ca normal; minor deviations are allowed if they
             do not impact on patient safety in the clinical judgment of the treating physician)

          -  Bilirubin â‰¤ 1.5 times upper limit of normal (ULN)

          -  ALT and AST â‰¤ 2.5 times ULN (â‰¤ 5 times ULN in the presence of documented liver
             metastases)

          -  Alkaline phosphatase â‰¤ 2.5 times ULN (â‰¤ 5 times ULN in the presence of liver or bone
             metastases)

          -  Not pregnant or nursing

          -  Fertile patients must use effective barrier contraception

          -  No uncontrolled intercurrent illness

          -  No active infection requiring systemic therapy

          -  Able to swallow oral medications and with no medical problems or prior surgeries that
             may interfere with the absorption of oral medications including the following:

               -  Uncontrolled nausea, vomiting, or diarrhea

               -  Lack of the physical integrity of the upper gastrointestinal tract

               -  Malabsorption syndrome

          -  No known hypersensitivity to bendamustine hydrochloride, mannitol, or erlotinib
             hydrochloride

          -  No prior malignancy in the past 5 years except for adequately treated basal cell or
             squamous cell skin carcinoma, or adequately treated stage I-II cancer for which the
             patient is in complete remission

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Prior adjuvant or neoadjuvant chemotherapy and 1 prior chemotherapy regimen in the
             metastatic setting allowed provided recovered from all acute toxicities

          -  No prior bendamustine hydrochloride or EGFR-directed therapy

          -  No other concurrent antineoplastic treatments, including radiotherapy, chemotherapy,
             biological therapy, hormonal therapy, immunotherapy, gene therapy, and surgery

               -  Intravenous bisphosphonates allowed

          -  No concurrent antiretroviral therapy for HIV-positive patients

          -  No other concurrent investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Layman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <results_reference>
    <citation>Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut EH, Shapiro CL. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemother Pharmacol. 2013 May;71(5):1183-90. doi: 10.1007/s00280-013-2112-2. Epub 2013 Feb 21.</citation>
    <PMID>23430121</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2009</study_first_submitted>
  <study_first_submitted_qc>January 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>September 26, 2014</results_first_submitted>
  <results_first_submitted_qc>March 31, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 22, 2015</results_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>male breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>estrogen receptor-negative breast cancer</keyword>
  <keyword>HER2-negative breast cancer</keyword>
  <keyword>progesterone receptor-negative breast cancer</keyword>
  <keyword>triple-negative breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bendamustine and Erlotinib</title>
          <description>Patients in dose level I were administered Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and 100 mg PO of Erlotinib on days 5 â€“ 21 of each 28 day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bendamustine and Erlotinib</title>
          <description>Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle.
bendamustine: 100 or 120 mg/m2 IV on days 1 and 2
erlotinib: 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle
Maintenance erlotinib: 150 mg po daily (days 1 - 28 of 28 day cycle)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="38" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG (Eastern Cooperative Oncology Group) performance status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 (Fully active)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 (Restricted)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 (Ambulatory and capable selfcare)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Site of metastasis</title>
          <description>A patient can be represented among multiple sites</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Lymph nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung/pleura</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest wall/skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior chemotherapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Adjuvant only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastasis/local recurrence only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total number of prior treatment regimens</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1 prior regimen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 prior regimens</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum-tolerated Dose of Bendamustine Hydrochloride (Phase I)</title>
        <description>28 day cycle included intravenous bendamustine on days 1 and 2.</description>
        <time_frame>Up to two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendamustine and Erlotinib</title>
            <description>Participants in dose level I were administered 100 mg/m^2 IV of Bendamustine on days 1 and 2 and 100 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.
Participants in dose level II were administered 120 mg/m^2 IV of Bendamustine on days 1 and 2 and 150 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum-tolerated Dose of Bendamustine Hydrochloride (Phase I)</title>
          <description>28 day cycle included intravenous bendamustine on days 1 and 2.</description>
          <units>mg/m^2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum-tolerated Dose of Erlotinib Hydrochloride (Phase I)</title>
        <description>28 day cycle included intravenous erlotinib on days 15-21.</description>
        <time_frame>Up to two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendamustine and Erlotinib</title>
            <description>Participants in dose level I were administered 100 mg/m^2 IV of Bendamustine on days 1 and 2 and 100 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.
Participants in dose level II were administered 120 mg/m^2 IV of Bendamustine on days 1 and 2 and 150 mg PO of Erlotinib on days 5 - 21 of each 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum-tolerated Dose of Erlotinib Hydrochloride (Phase I)</title>
          <description>28 day cycle included intravenous erlotinib on days 15-21.</description>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-limiting Toxicity (Phase I)</title>
        <time_frame>Up to two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendamustine and Erlotinib</title>
            <description>Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle.
bendamustine: 100 or 120 mg/m2 IV on days 1 and 2
erlotinib: 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle
Maintenance erlotinib: 150 mg po daily (days 1 - 28 of 28 day cycle)</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-limiting Toxicity (Phase I)</title>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose level I, n=5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose level II, n=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival at 6 Months and 12 Months (Phase II)</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>Up to two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendamustine and Erlotinib</title>
            <description>Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle.
bendamustine: 100 or 120 mg/m2 IV on days 1 and 2
erlotinib: 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle
Maintenance erlotinib: 150 mg po daily (days 1 - 28 of 28 day cycle)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival at 6 Months and 12 Months (Phase II)</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <units>months</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="1.7" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>Up to two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendamustine and Erlotinib</title>
            <description>Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle.
bendamustine: 100 or 120 mg/m2 IV on days 1 and 2
erlotinib: 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle
Maintenance erlotinib: 150 mg po daily (days 1 - 28 of 28 day cycle)</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose Level 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose Level 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Rate (CBR)</title>
        <time_frame>Up to two years</time_frame>
        <population>The data was not collected and analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Bendamustine and Erlotinib</title>
            <description>Patients in dose level I were administered Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and 100 mg PO of Erlotinib on days 5 â€“ 21 of each 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate (CBR)</title>
          <population>The data was not collected and analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DR)</title>
        <time_frame>Up to two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendamustine and Erlotinib</title>
            <description>Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle.
bendamustine: 100 or 120 mg/m2 IV on days 1 and 2
erlotinib: 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle
Maintenance erlotinib: 150 mg po daily (days 1 - 28 of 28 day cycle)</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DR)</title>
          <units>months to progression</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="1.7" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <time_frame>from time of study enrollment until death, for up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendamustine and Erlotinib</title>
            <description>Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle.
bendamustine: 100 or 120 mg/m2 IV on days 1 and 2
erlotinib: 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle
Maintenance erlotinib: 150 mg po daily (days 1 - 28 of 28 day cycle)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="3.6" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship of EGFR Expression or Amplification, Basal-like Tumors, and DNA Damage-repair Checkpoint Activation With ORR, CBR, DR, and OS</title>
        <time_frame>up to two years</time_frame>
        <population>Correlative studies to assess EGFR expression and gene amplification, were planned, but not collected because of early trial termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendamustine and Erlotinib</title>
            <description>Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle.
bendamustine: 100 or 120 mg/m2 IV on days 1 and 2
erlotinib: 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle
Maintenance erlotinib: 150 mg po daily (days 1 - 28 of 28 day cycle)</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship of EGFR Expression or Amplification, Basal-like Tumors, and DNA Damage-repair Checkpoint Activation With ORR, CBR, DR, and OS</title>
          <population>Correlative studies to assess EGFR expression and gene amplification, were planned, but not collected because of early trial termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from beginning of cycle 1 treatment through end of treatment, for up to 2 years</time_frame>
      <desc>This study will utilize the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 3.0 for toxicity and Serious Adverse Event reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bendamustine and Erlotinib</title>
          <description>Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle.
bendamustine: 100 or 120 mg/m2 IV on days 1 and 2
erlotinib: 100 or 150 mg po on days 5 â€“ 21 of each 28 day cycle
Maintenance erlotinib: 150 mg po daily (days 1 - 28 of 28 day cycle)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE version 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE version 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Consitutional</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>CD4 count</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rachel Layman, MD</name_or_title>
      <organization>The Ohio State University Comprehensive Cancer Center</organization>
      <phone>614-366-8541</phone>
      <email>Rachel.Layman@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

